Taiwan · Delayed Price · Currency is TWD BRIM Biotechnology Company Description
BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan.
The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease.
It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis.
BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Wenqi Xu |
Contact Details
Address: No.1, Alley 30 Taipei, 11492 Taiwan | |
| Phone | 886 2 2659 8586 |
| Website | brimbiotech.com |
Stock Details
| Ticker Symbol | 6885 |
| Exchange | Taiwan Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wenqi Xu Ph.D. | Chief Executive Officer and GM |
| Shen Lin M.B.A., M.S. | Chairman and Chief Investment Officer |
| Dr. Haishan Jang M.B.A., Ph.D. | Vice Chairman and Chief Global Strategist |
| Wen Chyi Shyu | President |
| Jiadian Yan | Vice President of Finance and Accounting Supervisor |
| Kuo Mei-Hui M.S. | Chief Operating Officer |
| Dr. Frank W. Lee Ph.D. | Chief Scientific Officer |
| Cheng-Wen Lin Ph.D. | Chief Technology Officer |
| Yi-Chun Chen | Vice President of Business Development |